209 related articles for article (PubMed ID: 35031563)
41. EZH2 suppresses the nucleotide excision repair in nasopharyngeal carcinoma by silencing XPA gene.
Huang Y; Wang X; Niu X; Wang X; Jiang R; Xu T; Liu Y; Liang L; Ou X; Xing X; Li W; Hu C
Mol Carcinog; 2017 Feb; 56(2):447-463. PubMed ID: 27253463
[TBL] [Abstract][Full Text] [Related]
42. EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma.
Yan J; Li B; Lin B; Lee PT; Chung TH; Tan J; Bi C; Lee XT; Selvarajan V; Ng SB; Yang H; Yu Q; Chng WJ
Blood; 2016 Aug; 128(7):948-58. PubMed ID: 27297789
[TBL] [Abstract][Full Text] [Related]
43. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
[TBL] [Abstract][Full Text] [Related]
44. Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.
Kim J; Lee Y; Lu X; Song B; Fong KW; Cao Q; Licht JD; Zhao JC; Yu J
Cell Rep; 2018 Dec; 25(10):2808-2820.e4. PubMed ID: 30517868
[TBL] [Abstract][Full Text] [Related]
45. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
[TBL] [Abstract][Full Text] [Related]
46. Beyond Expression: Role of Phosphorylated Residues of EZH2 in Lineage Plasticity in Prostate Cancer.
Nouruzi S; Tabrizian N; Zoubeidi A
Endocrinology; 2023 Feb; 164(4):. PubMed ID: 36718085
[TBL] [Abstract][Full Text] [Related]
47. Conditionally replicative adenovirus carrying shRNA targeting EZH2 inhibits prostate cancer growth and invasion.
Xu SG; Yu JJ; Shi Q; Niu Q; Guo Z; Guo BY; Zhou GC; Gu X; Wu YX
Oncol Rep; 2019 Jul; 42(1):273-282. PubMed ID: 31115564
[TBL] [Abstract][Full Text] [Related]
48. Epigenetic regulation of enhancer of zeste homolog 2 (EZH2) -Yin Yang 1 (YY1) axis in cancer.
Chandnani N; Gupta I; Thakkar V; Sarkar K
Pathol Res Pract; 2023 Nov; 251():154885. PubMed ID: 37862922
[TBL] [Abstract][Full Text] [Related]
49. Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2.
Mukhopadhyay NK; Kim J; You S; Morello M; Hager MH; Huang WC; Ramachandran A; Yang J; Cinar B; Rubin MA; Adam RM; Oesterreich S; Di Vizio D; Freeman MR
Oncogene; 2014 Jun; 33(25):3235-45. PubMed ID: 23893242
[TBL] [Abstract][Full Text] [Related]
50. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
Christofides A; Karantanos T; Bardhan K; Boussiotis VA
Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
[TBL] [Abstract][Full Text] [Related]
51. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z
BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081
[TBL] [Abstract][Full Text] [Related]
52. Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion.
Nolan KD; Franco OE; Hance MW; Hayward SW; Isaacs JS
J Biol Chem; 2015 Mar; 290(13):8271-82. PubMed ID: 25670862
[TBL] [Abstract][Full Text] [Related]
53. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
54. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
55. DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.
Zhang L; Li HT; Shereda R; Lu Q; Weisenberger DJ; O'Connell C; Machida K; An W; Lenz HJ; El-Khoueiry A; Jones PA; Liu M; Liang G
Cancer Lett; 2022 Nov; 548():215899. PubMed ID: 36087682
[TBL] [Abstract][Full Text] [Related]
56. EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
Zong X; Wang W; Ozes A; Fang F; Sandusky GE; Nephew KP
Cancer Res; 2020 Oct; 80(20):4371-4385. PubMed ID: 32816909
[TBL] [Abstract][Full Text] [Related]
57. EZH2 inhibitors: a patent review (2014-2016).
Stazi G; Zwergel C; Mai A; Valente S
Expert Opin Ther Pat; 2017 Jul; 27(7):797-813. PubMed ID: 28394193
[TBL] [Abstract][Full Text] [Related]
58. Coexpression Analysis of the EZH2 Gene Using The Cancer Genome Atlas and Oncomine Databases Identifies Coexpressed Genes Involved in Biological Networks in Breast Cancer, Glioblastoma, and Prostate Cancer.
Zhu J; Jin L; Zhang A; Gao P; Dai G; Xu M; Xu L; Yang D
Med Sci Monit; 2020 Jun; 26():e922346. PubMed ID: 32595202
[TBL] [Abstract][Full Text] [Related]
59. EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
Tiffen J; Gallagher SJ; Filipp F; Gunatilake D; Emran AA; Cullinane C; Dutton-Register K; Aoude L; Hayward N; Chatterjee A; Rodger EJ; Eccles MR; Hersey P
J Invest Dermatol; 2020 Dec; 140(12):2442-2454.e5. PubMed ID: 32360600
[TBL] [Abstract][Full Text] [Related]
60. Going beyond Polycomb: EZH2 functions in prostate cancer.
Park SH; Fong KW; Mong E; Martin MC; Schiltz GE; Yu J
Oncogene; 2021 Sep; 40(39):5788-5798. PubMed ID: 34349243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
